Adamas Pharmaceuticals, Inc.

Gen-probe, Inc.

Adamas Pharma, LLC

Chiron Corporation

Adamas Pharmacueticals, Inc.

Adamas Pharmaceutical, Inc.

Timothy J Fultz

Gregory T Went

Laurence R Meyerson

Seth Porter

Timothy S Burkoth

Daniel L Kacian

Natalie McClure

Sangita Ghosh

Michael S Urdea

Brian David Warner

David Chernoff

Jack Nguyen

Sherrol Hoffa McDonough

Thomas Horn

Terry L Burkoth

Mark L Collins

Chu-an Chang

Mickey S Urdea

Rowan Chapman

Paul Spence

Timothy Burkoth

Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.

Amantadine compositions, preparations thereof, and methods of use

Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

Methods of administering amantadine

Methods of using amantadine compositions

Amantadine compositions and preparations thereof

Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Methods and compositions for the treatment of seizure-related disorders

Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.

Composition and method for treating neurological disease

A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.

Growing community of inventors

Pleasant Hill, CA, United States of America

Timothy J Fultz